Treatment patterns and clinical outcomes in triple-class exposed patients with relapsed or refractory multiple myeloma: Real-world data from two hospitals in Japan

DOI

この論文をさがす

抄録

<p>The KarMMa-Real World (RW) study showed treatment variability and suboptimal outcomes for triple-class exposed (TCE) patients with relapsed or refractory multiple myeloma (RRMM). This retrospective analysis of de-identified electronic health records from the KarMMa-RW study evaluated characteristics, treatments, and outcomes for TCE patients with RRMM in two hospitals in Japan. Date of refractory treatment status was the index date. Patients with a new post-index treatment (RRMM-Treatment) or no post-index treatment (RRMM-No Treatment) were followed until death or last known date alive. Patient characteristics, post-index treatments, overall response rate (ORR), time to response (TTR), duration of response (DOR), overall survival (OS), and progression-free survival (PFS) were summarized. Twenty-two patients were eligible for analysis (RRMM-Treatment, n = 14; and RRMM-No Treatment, n = 8). The RRMM-Treatment group had an ORR of 21.4%, median TTR of 22 days, and median DOR of 180 days. Median OS was 20.5 months (95% CI 20.5–not estimable) for the RRMM-Treatment group and 8.9 months (95% CI 0.1–22.7) for the RRMM-No Treatment group. Median PFS was 4.8 months (95% CI 1.9–6.7) for the RRMM-Treatment group. We observed a substantial disease burden, suggesting a need for more effective treatment options for TCE Japanese patients with RRMM.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ